The association between glycaemic control during hospitalization and risk of adverse events: A retrospective cohort study

Lan Deng1 | Wusiman Aibibula2 | Zahra Talat1 | Kristian B. Filion1,2,3 | Shaun Eintracht4 | Kaberi Dasgupta5,6 | Vicky Tagalakis1,3,7 | Agnieszka Majdan8 | Oriana Hoi Yun Yu3,8

1Department of Medicine, McGill University, Montreal, QC, Canada
2Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada
3Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
4Department of Internal Medicine, Division of Medical Biochemistry, Jewish General Hospital, McGill University, Montreal, QC, Canada
5Divisions of Internal Medicine, Endocrinology and Metabolism, and Epidemiology, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada
6Centre for Events Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montréal, QC, Canada
7Department of Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada
8Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada

Correspondence:
Oriana Hoi Yun Yu, Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, 375 Côte Sainte-Catherine, E104, Montreal, Quebec H3T 1E2, Canada.
Email: hoi.yu@mcgill.ca

Abstract

Introduction: Hyperglycaemia is common during hospitalization; glycaemic targets in non-critical care settings have not been well studied. We assessed associations between inpatient glycaemic control and adverse events.

Methods: We conducted a retrospective cohort study on non-critically ill medical patients hospitalized in a tertiary care hospital between 2015 and 2018. Mean glycaemia during the first four days of hospitalization was categorized as 4.0–7.0 mmol/L, 7.1–10.0 mmol/L and >10.0 mmol/L. The primary outcome was a composite of adverse events including mortality, infections, acute kidney injury, thromboembolic and cardiovascular events. The secondary outcome was hypoglycaemia, defined as any glycaemia <4.0 mmol/L. Logistic regression was used to assess adverse events, and a Cox proportional hazards model was used to estimate hypoglycaemia risk.

Results: Our cohort included 1,368 patients, of whom 407 (29.8%) experienced an adverse event. We did not find associations between glycaemia of 4.0–7.0 mmol/L (adjusted odds ratio [OR]: 0.88, 95% confidence interval [CI]: 0.63–1.23) or glycaemia of >10.0 mmol/L (adjusted OR: 0.98, 95% CI: 0.75–1.28) and the occurrence of adverse events, compared to a glycaemia of 7.1–10.0 mmol/L. Glycaemia of >10.0 mmol/L was associated with an increased risk of hypoglycaemia (adjusted hazard ratio [HR]: 1.72,
Hyperglycaemia is common among hospitalized patients with a prevalence of up to 38\%.\(^1\) Common causes for hyperglycaemia among hospitalized patients include increased secretion of stress hormones, use of glucocorticoids and failure to re-initiate anti-diabetic medications.\(^2,3\) Studies have shown that hyperglycaemia in various clinical settings is associated with adverse patient outcomes, including infections, cerebrovascular and cardiovascular events, prolonged hospital stay and death.\(^1,4–11\) Potential mechanisms by which hyperglycaemia may lead to these adverse events include impairment of neutrophil and macrophage function, decreasing lymphocytes, enhancing platelet activation, decreasing tissue plasminogen activator and plasma fibrinolytic activity, and impairment of myocardial glucose utilization.\(^12–17\) Furthermore, hyperglycaemia has been found to cause endothelial dysfunction and increase oxidative stress.\(^18,19\) Some of these processes have been shown to improve with lowering of glucose levels to normal range.\(^20–22\)

Nevertheless, in-hospital glycaemic control is often neglected as care is focussed on the underlying presentation of illness.\(^23\) The American Diabetes Association recommends a target random blood glucose of 7.8 mmol/L to 10.0 mmol/L for the majority of hospitalized patients. More stringent goals between 6.1 and 7.8 mmol/L may be appropriate for selected patients if they can be achieved without significant hypoglycaemia. These targets are extrapolated from randomized controlled trials conducted mainly in the critically ill patient population.\(^24\) For non-critically ill patients, the association between glycaemic control and adverse outcomes has not been extensively studied, and the limited number of studies conducted to date has inconsistent results.\(^25\) A meta-analysis of 19 studies by Murad et al.\(^25\) reported no association between intensive glycaemic control and the risk of mortality, myocardial infarction or stroke among non-critically ill hospitalized patients with diabetes; however, the studies included were heterogeneous and the evidence was mainly derived from surgical patients. To further understand the effects of glycaemic control during non-critical care hospitalization in medical patients, we conducted a retrospective study to determine the association between glycaemic control and adverse events among medical patients admitted to non-critical care units.

### 2 | METHODS

#### 2.1 | Study design and population

We conducted a retrospective cohort study using electronic health records of patients treated at the Jewish General Hospital, a tertiary care teaching hospital for adult patients located in Montréal, Quebec, Canada. For each patient admitted to internal medicine units between 1 January 2015 and 31 December 2018, we obtained the discharge abstract from the medical records department and laboratory data from the biochemistry database. The discharge abstracts included the primary and secondary diagnoses of each patient, as well as new diagnoses and complications that arose during hospitalization documented by the treating physician. Patients carried a variety of common internal medicine admission diagnoses, including haematology-oncology patients who required hospitalization. All medical diagnoses were recorded using International Classification of Diseases (ICD)-10 codes. The study protocol was approved by the Research Ethics Committee at the Jewish General Hospital, Montréal, Canada.

We included patients aged 18 years or older with at least two capillary glucose measurements performed daily during the first four days of hospitalization. Capillary glucose measurements are performed routinely in patients with a history of diabetes during hospitalization, before meals and at bedtime, and more frequently should hypoglycaemia occur. As such, patients with various types of diabetes were included. Patients with diagnoses of pregnancy, diabetic ketoacidosis and non-ketotic hyperglycaemic-hyperosmolar state at the time of admission were excluded.

#### 2.2 | Exposure

The mean glycaemia during the first four days of hospitalization were calculated and classified into three categories for the purpose of this study: 4.0–7.0 mmol/L, 7.1–10.0 mmol/L (reference group) and >10.0 mmol/L. In an attempt to minimize protopathic bias, the first four days of glycaemic data were arbitrarily collected, based on previous studies that demonstrated length of medical hospitalization to be around 6 to 8.5 days.\(^8,26\) Hypoglycaemia was defined as having any glycaemia less than 4.0 mmol/L during hospitalization.\(^24,27\)

### KEYWORDS

- adverse events
- cohort study
- glycaemic target
During the study period, clinical practice in the management of hyperglycaemia was relatively unchanged. The only novel anti-diabetic agent introduced was the sodium-glucose cotransporter (SGLT)-2 inhibitors which were available from 2 February 2015 in the Quebec public formulary. At the Jewish General Hospital, there are standardized insulin sliding scale protocols that physicians generally prescribe for patients with diabetes. The insulin sliding scale protocol can be adjusted by the treating physician if necessary, to help prevent hypo- or hyperglycaemia during hospitalization.

2.3 | Outcomes

The primary outcome was a composite of infections (urinary tract infection, pneumonia, Clostridium difficile and other infectious colitis, cellulitis, wound ulcer and sepsis), thromboembolic events (pulmonary embolism, deep vein thrombosis), cardiovascular events (myocardial infarction, unstable angina, ischaemic stroke and transient ischaemic attack), acute kidney injury and all-cause mortality that occurred during hospitalization. The secondary outcome was hypoglycaemia, defined as having any glycaemia of <4.0 mmol/L anytime during the entire hospitalization, with the event date defined by the date of the laboratory result of glycaemia <4.0 mmol/L.

2.4 | Statistical analyses

Mean and standard deviations for continuous variables, and number and proportions for categorical variables were calculated, stratified by exposure groups. We used a multiple logistic regression model to estimate the adjusted odds ratios (OR) and 95% confidence interval (CI) of the primary composite end-point for a mean glycaemia of 4.0–7.0 mmol/L and a mean glycaemia of >10.0 mmol/L versus a mean glycaemia of 7.1–10.0 mmol/L. In secondary analyses, we used a Cox proportional hazards model to estimate the adjusted hazard ratios (HR) and corresponding 95% CI of hypoglycaemia for a mean glycaemia of 4.0–7.0 mmol/L and a mean glycaemia of >10.0 mmol/L versus a mean glycaemia of 7.1–10.0 mmol/L. To determine the risk of adverse events associated with hypoglycaemia during hospitalization, we used a multiple logistic regression model to estimate the adjusted OR and 95% CI of the primary composite end-point in association with hypoglycaemia during hospitalization. All models were adjusted for the following potential confounding: age, sex, serum creatinine level measured at time of admission, use of cholesterol-lowering agents, antihypertensives, diuretics, antiplatelets, anticoagulants and glucocorticoids documented at the time of admission.

2.5 | Sensitivity analyses

The primary analysis was performed to assess the association between having a mean glycaemia of 4.0–7.0 mmol/L or a mean glycaemia of >10.0 mmol/L versus a mean glycaemia of 7.1–10.0 mmol/L during the first four days of hospitalization and the risk of all-cause mortality. The primary and secondary analyses were repeated using average glycaemia during the entire hospitalization rather than only the first 4 days of hospitalization, to assess the association with the risk of primary composite outcome and hypoglycaemia.

3 | RESULTS

A total of 1368 patients were included in the study. The distributions for age, sex and serum creatinine were comparable among the groups (Table 1). Patients with a mean glycaemia of 4.0–7.0 mmol/L had lower prevalence of use of anti-diabetic medications, cholesterol-lowering medications, anti-hypertensive medications, diuretics, antiplatelets and glucocorticoids during hospitalization, compared to patients in the other two exposure categories. The average length of hospitalization was 18 ± 27 days in the mean glycaemia 4.0–7.0 mmol/L group, 16 ± 19 days in the mean glycaemia 7.1–10.0 mmol/L group and 15 ± 23 days in the mean glycaemia >10.0 mmol/L group.

A total of 407 patients (29.8%) experienced the adverse event composite end-point (Table 2). The cumulative risk of the composite end-point was 30.5% among those with a mean glycaemia of 7.1-10.0 mmol/L, 31.0% among those with a mean glycaemia of >10.0 mmol/L and 28.0% among those with a mean glycaemia of 4.0–7.0 mmol/L. Compared with a mean glycaemia of 7.1–10.0 mmol/L, a mean glycaemia of 4.0–7.0 mmol/L during the first 4 days of hospitalization was not associated with the occurrence of the primary composite end-point (adjusted OR 0.88, 95% CI 0.63–1.23). Similarly, a mean glycaemia of >10.0 mmol/L during the 4 days of hospitalization was not associated with the occurrence of the primary composite end-point (adjusted OR 0.98, 95% CI 0.75–1.28). The majority of adverse events recorded was all-cause mortality in all three exposure groups (Table S1).

Compared with a mean glycaemia of 7.1–10.0 mmol/L, a mean glycaemia of >10.0 mmol/L during the first four days of hospitalization was associated with an increased risk of hypoglycaemia (adjusted HR 1.72, 95% CI 1.21–2.45) (Table 3). In contrast, a mean glycaemia of 4.0–7.0 mmol/L was not associated with an increased risk of hypoglycaemia (adjusted HR 1.29, 95% CI 0.84–1.98). Hypoglycaemia during hospitalization was associated with an increased risk of the primary composite outcome (adjusted OR 1.85, 95% CI 1.31–2.60) (Table 4).

Sensitivity analysis assessing the risk of all-cause mortality associated with a mean glycaemia of 4.0–7.0 mmol/L and >10.0 mmol/L compared to a mean glycaemia of 7.1–10.0 mmol/L resulted in consistent findings (mean glycaemia 4.0–7.0 mmol/L adjusted OR: 0.86; 95% CI: 0.61–1.20 and mean glycaemia >10.0 mmol/L adjusted OR: 0.99; 95% CI: 0.76–1.30) (Table S2). Additional sensitivity analyses were performed with mean glycaemia from the entire hospitalization. Of note, the mean glucose in the three groups using glycaemic
TABLE 1 Baseline characteristics of patients with mean glycaemia of 4.0–7.0, 7.1–10.0 and >10.0 mmol/L during the first 4 days of hospitalization

| Characteristics                  | Glucose 4.0–7.0 mmol/L | Glucose 7.1–10.0 mmol/L | Glucose >10.0 mmol/L | Entire cohort |
|----------------------------------|------------------------|-------------------------|----------------------|--------------|
|                                  | n or mean % or SD      | n or mean % or SD       | n or mean % or SD    | n or mean % or SD |
| Number of patients, n (%)        | 270 19.7               | 565 41.3                | 533 39               | 1368 100     |
| Glucose, mean (SD)               | 6.1 0.7                | 8.5 0.8                 | 12.7 2.3             | 9.6 3        |
| Length of stay, days (SD)        | 18 27                  | 16 19                   | 15 23                | 16 23        |
| Age (years), mean (SD)           | 69.6 15.2              | 70.3 15.3               | 71.6 14              | 70.7 14.8    |
| 18–40, n (%)                     | 12 20.7                | 32 55.2                 | 14 24.1              | 58 4.2       |
| 41–50, n (%)                     | 15 27.3                | 19 34.6                 | 21 38.2              | 55 4.0       |
| 51–60, n (%)                     | 47 23.7                | 78 39.4                 | 73 36.9              | 198 14.5     |
| 61–70, n (%)                     | 60 18.5                | 133 41.1                | 131 40.4             | 324 23.6     |
| 71–80, n (%)                     | 67 19.3                | 145 41.7                | 136 39.1             | 348 25.4     |
| 81–90, n (%)                     | 50 16.2                | 130 42.2                | 128 41.6             | 308 22.5     |
| 91+, n (%)                       | 19 24.7                | 28 36.4                 | 30 39                | 77 5.6       |
| Male, n (%)                      | 156 57.8               | 318 56.3                | 304 57               | 780 57.0     |
| Serum creatinine (μmol/L), mean (SD) | 148 161.4             | 170.2 169               | 162.4 163.4          | 162.6 165.3  |
| Anti-diabetic use, n (%)         | 141 52.2               | 450 79.7                | 494 92.7             | 1085 79.3    |
| α glucosidase inhibitors         | 1 0.4                  | 2 0.4                   | 3 0.6                | 6 0.4        |
| DPP-4 inhibitors<sup>a</sup>     | 37 13.7                | 132 23.4                | 178 33.4             | 347 25.4     |
| GLP-1 agonists<sup>b</sup>       | 2 0.7                  | 2 0.4                   | 5 0.9                | 9 0.7        |
| Insulin                          | 57 21.1                | 216 38.2                | 316 59.3             | 589 43.1     |
| Meglitinides                     | 6 2.2                  | 13 2.3                  | 10 1.9               | 29 2.1       |
| Metformin                        | 98 36.3                | 275 48.7                | 318 59.7             | 691 50.5     |
| SGLT2 inhibitors<sup>c</sup>     | 1 0.4                  | 23 4.1                  | 9 1.7                | 33 2.4       |
| Sulfonylureas                    | 26 9.6                 | 114 20.2                | 149 28.0             | 289 21.1     |
| Thiazolidinediones               | 1 0.4                  | 9 1.6                   | 3 0.6                | 13 1.0       |
| Anti-coagulant use, n (%)        | 78 28.9                | 157 27.8                | 166 31.1             | 402 29.4     |
| Anti-hypertensive use, n (%)     | 187 69.3               | 456 80.7                | 415 77.9             | 1060 77.5    |
| Antiplatelet use, n (%)          | 105 38.9               | 264 46.7                | 248 46.5             | 617 45.1     |
| Diuretic use, n (%)              | 94 34.8                | 263 46.6                | 262 49.2             | 620 45.3     |
| Glucocorticoid use, n (%)        | 47 17.4                | 132 23.4                | 137 25.7             | 316 23.1     |
| Hypolipidemic use, n (%)         | 141 52.2               | 364 64.4                | 333 62.5             | 838 61.3     |
|<sup>a</sup>DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors.  
<sup>b</sup>GLP-1 agonists: Glucagon-like peptide-1 receptor agonists.  
<sup>c</sup>SGLT2 inhibitors: Sodium-glucose cotransporter-2 inhibitors.

TABLE 2 Crude and adjusted odds ratios for the association between mean glycaemia in the first four days and the risk of adverse outcomes during hospitalization<sup>a</sup>

| Mean glycaemic level (mmol/L) | Number of patients with composite primary outcome (%) | Number of patients at risk | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-------------------------------|------------------------------------------------------|----------------------------|--------------------|----------------------|
| 4.0–7.0                       | 74 (28.0)                                             | 264                        | 0.89 (0.64, 1.23)  | 0.88 (0.63, 1.23)    |
| 7.1–10.0                      | 170 (30.5)                                            | 557                        | Reference          | Reference            |
| > 10.0                        | 163 (31.0)                                            | 525                        | 1.03 (0.79, 1.33)  | 0.98 (0.75, 1.28)    |

Abbreviations: CI, confidence intervals; OR, odds ratio.  
<sup>a</sup>22 observations were deleted due to missing values (6 from the mean glycaemia 4.0–7.0 mmol/L group, 8 from the mean glycaemia 7.1–10.0 mmol/L group and 8 from the mean glycaemia >10.0 mmol/L group). Analyses were adjusted for age, sex, creatinine level, use of cholesterol-lowering agents, antihypertensives, antiplatelets, anticoagulants and glucocorticoids.
TABLE 3  Crude and adjusted hazard ratios for the association between average glycaemia in the first 4 days and the risk of hypoglycaemia during hospitalization

| Mean glycaemic level (mmol/L) | Number of hypoglycaemia events (%) | Number of patients at risk | Crude HR (95% CI) | Adjusted HR (95% CI) |
|------------------------------|------------------------------------|---------------------------|-------------------|---------------------|
| 4.0–7.0                     | 36 (13.6)                           | 265                       | 1.34 (0.88, 2.04) | 1.29 (0.84, 1.98)   |
| 7.1–10.0                    | 55 (9.9)                            | 557                       | Reference         | Reference           |
| > 10.0                      | 75 (14.3)                           | 525                       | 1.76 (1.24, 2.49) | 1.72 (1.21, 2.45)   |

Abbreviations: CI, confidence intervals; HR, hazard ratio.

A 21 observations were deleted due to missing values (5 from the mean glycaemia 4.0–7.0 mmol/L group and 8 from the mean glycaemia 7.1–10.0 mmol/L group). Analyses were adjusted for age, sex, creatinine level, use of cholesterol-lowering agents, antihypertensives, antiplatelets, anticoagulants and glucocorticoids.

TABLE 4  Crude and adjusted odds ratios for the association between hypoglycaemia and the risk of adverse outcomes during hospitalization

| Occurrence of hypoglycaemia | Number of patients with composite primary outcome | Number of patients at risk | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-----------------------------|-----------------------------------------------|---------------------------|-------------------|---------------------|
| No                          | 338                                           | 1181                      | Reference         | Reference           |
| Yes                         | 71                                            | 167                       | 1.85 (1.32, 2.57) | 1.85 (1.31, 2.60)   |

Abbreviations: CI, confidence intervals; OR, odds ratio.

A 20 observations were deleted due to missing values (20 from the no occurrence of hypoglycaemia group and 0 from the occurrence of hypoglycaemia group). Analyses were adjusted for age, sex, creatinine level, use of cholesterol-lowering agents, antihypertensives, antiplatelets, anticoagulants and glucocorticoids.

data from the entire hospitalization was comparable to using glycaemic data from the first four days of hospitalization (Table S3). Similar to the primary analysis findings, there was no association between average glycaemia during the entire hospitalization and the risk of primary composite outcome (Table S4). There was no association between average glycaemia during the entire hospitalization and the risk of hypoglycaemia (Table S5).

4 | DISCUSSION

In this study, there was no association between a mean glycaemia of 4.0–7.0 mmol/L or a mean glycaemia of >10.0 mmol/L and risk of adverse events among hospitalized patients in non-critical care internal medicine units, compared to patients with a mean glycaemia of 7.1–10.0 mmol/L. The mean length of hospitalization was similar between patients in the three glycaemia categories. Having a mean glycaemia of >10.0 mmol/L during the first four days of hospitalization was associated with a 72% increased risk of hypoglycaemia. Hypoglycaemia during hospitalization was associated with a nearly twofold higher risk of adverse events.

Although there is growing clinical evidence indicating the need for treating hyperglycaemia among hospitalized patients with diabetes, the management of hyperglycaemia is challenging, and the optimal glycaemia target has not been well studied.25 Currently suggested targets are difficult to achieve given that it requires more effort and the risk of hypoglycaemia may increase when the glycaemia is targeted to a lower range within normal. Clinical studies have shown that tight glycaemic control may improve outcomes among patients with acute coronary syndrome via reducing oxidative stress and inflammation.30–32 However, two large randomized clinical trials, DIGAMI and NICE-SUGAR, which involved cardiac and intensive care patients, respectively, have provided conflicting results on the risk of mortality associated with intensive glycaemic control during hospitalization.33,34 Thus, the practice of using intensive insulin therapy to achieve tight glycaemic control among critically ill patients has not been justified by these studies given such practice may not improve mortality and can increase the risk of hypoglycaemia.34 Studies performed so far on non-critically ill patients are fewer, and most studies have shown an increased risk of adverse outcomes among hospitalized patients with hyperglycaemia.14–11,26 In our study, having a glycaemia of >10.0 mmol/L was not found to be associated with an increased risk of adverse outcomes. The meta-analysis by Murad et al.23 demonstrated similar results; intensive glycaemic control, defined largely by fasting blood glucose level between 5.6 to 10 mmol/L, was not associated with reductions of mortality, myocardial infarction or stroke risks. However, this meta-analysis found an association between intensive glycaemic control and reduced infection risk, predominantly in surgical patients.

There are a few possible explanations for the null finding in our study. First, our sample size may have been insufficient to allow for the detection of smaller but clinically important differences in the risk of adverse events among different glycaemic control groups. Second, the internal medicine units in this study are teaching units staffed by a large team of attending physicians, resident physicians and medical students. As such, there are usually actions taken to
address hyperglycaemia in a timely fashion. Patients with abnormal test results such as hyperglycaemia may have received more medical attention.

The findings from our secondary outcome suggest that having a glycaemia of >10.0 mmol/L during the 4 days of hospitalization was associated with a higher risk of hypoglycaemia, whereas having a glycaemia of 4.0–7.0 mmol/L was not associated with an increased risk of hypoglycaemia. In the literature, having lower glycaemia within the recommended target range is generally associated with a higher risk of hypoglycaemia, with most evidence derived from critically ill or post-myocardial infarction patients.35-37

In our study, the percentage of patients with mean glycaemia 4.0–7.0 mmol/L who experienced hypoglycaemia is similar to that of patients with the mean glycaemia >10.0 mmol/L; our sample size may have been insufficient to allow detection of significant hypoglycaemia risk in those with the mean glycaemia of 4.0–7.0 mmol/L. The increased hypoglycaemia risk in patients with a mean glycaemia of >10.0 mmol/L during the first four days of hospitalization may be due to usage of insulin and particularly insulin sliding scale, to treat hyperglycaemia and that these patients are more susceptible to hypoglycaemia with insulin treatment. Patients with a mean glycaemia of >10.0 mmol/L during the entire hospitalization were not found to be at increased risk of hypoglycaemia, suggesting that patients with hyperglycaemia throughout hospitalization do not have an increased risk of hypoglycaemia. Intensive insulin therapy has been shown to be associated with an increased risk of hypoglycaemia in the critical care setting.38 Furthermore, insulin sliding scale has been shown in some studies to increase the risk of both hyperglycaemia and hypoglycaemia.39 Further studies are needed to understand the relationship between glycaemic control during hospitalization and hypoglycaemia risk.

Hypoglycaemia during hospitalization was associated with a nearly twofold increase in the risk of adverse outcomes. Hypoglycaemia during hospitalization has been associated with an increased risk of all-cause mortality (HR: 2.55; 95% CI: 2.25–2.88) in a retrospective study of patients aged ≥66 years over a 4 year follow-up period.40 Hypoglycaemia has been shown to be associated with an increased risk of vascular outcomes and all-cause mortality in the outpatient setting.41,42 Although it is possible that hypoglycaemia may contribute to increased risks of vascular complications and all-cause mortality, hypoglycaemia may also act as a marker of increased comorbidity and thus predicts a higher risk of all-cause mortality. Nevertheless, the findings from our study suggest that hypoglycaemia should be avoided during hospitalization. Further studies are warranted to determine whether there is a causal relationship between hypoglycaemia and an increased risk of adverse outcomes during hospitalization.

Interestingly, we found an association between having a mean glycaemia of >10.0 mmol/L and increased hypoglycaemia risk, and an association between hypoglycaemia and risk of adverse events, while there was no association between having mean glycaemia of >10.0 mmol/L and risk of adverse events. Possible explanations for this include that there are factors other than the proposed use of insulin and insulin sliding scale contributing to hypoglycaemia, for example terminal frailty, unreliable oral intake or severe underlying illnesses that is associated with hypoglycaemia and an increased risk of death. Thus, iatrogenic hypoglycaemia is unlikely to be associated with increased adverse events compared to spontaneous hypoglycaemia.42 Further studies are needed to assess glycaemic control and risk of hypoglycaemia during hospitalization.

This study has some strengths. First, to our knowledge, this is the first study to assess various glycaemia cut-offs within the recommended glycaemia target to further discern optimal glycaemia management during non-critical care hospitalization. Second, we were able to adjust for a number of confounders, including usage of a few medication classes which are reflective of underlying patient comorbidities. Third, in order to minimize protopathic bias, glycaemic control was calculated based on glycaemia during the first four days of hospitalization only.

This study also has limitations. First, patients with various types of diabetes were included in the study. The current in-hospital glycaemia targets in guidelines do not distinguish types of diabetes. However, it is reasonable to suspect that adverse effects of hyperglycaemia may differ based on the underlying mechanism causing hyperglycaemia. Second, as the vast majority of adverse events recorded were deaths, the number of events was insufficient to examine the risks of the individual components of our composite end-point (Table S1). Third, we were unable to obtain the date of adverse events that occurred during hospitalization. Therefore, in our primary analysis, some adverse events may have happened during the first four days of hospitalization, leading to potential risk of reverse causality. However, the risk of reverse causality unlikely had significant contribution to the results, as most adverse events recorded were mortalities (Table S1). Fourth, measurements for severity of diabetes and insulin dosing used during hospitalization were not available in our databases, and thus, the analyses did not adjust for diabetes severity or duration. Similarly, we do not have information on the nutritional status of the patients during hospitalization, which may affect glycaemic control. Fifth, we were unable to adjust for the severity of patients’ presenting illness due to the heterogeneity of admission diagnoses. Sixth, the averaged glucose values do not account for situations where glucose may have been repeatedly checked over a short period of time, for example when treating hypoglycaemia, which may have skewed the mean glucose values. However, only 20 patients had hypoglycaemia during the first four days of hospitalization. Seventh, the study focussed on glycaemic control and adverse events during hospitalization. As such, some complications such as mortality, cardiovascular events, infection may take time to develop and may happen after a hospitalization. Unfortunately, our study was unable to assess outcomes that occurred after hospital discharge. Finally, as this is an observational study, there may be residual confounding.
5 | CONCLUSIONS

For non-critically ill patients hospitalized on internal medicine units, neither having a mean glycaemia of 4.0–7.0 mmol/L nor a mean glycaemia of >10 mmol/L was associated with increased risks of adverse events. The result for having a mean glycaemia of >10 mmol/L was unexpected and may be due to increased medical attention given to these patients and timely intervention given to lower glycaemia. Mean glycaemia of >10 mmol/L was associated with a higher risk of hypoglycaemia, likely attributable to aggressive glucose lowering measures, arguing for more attention on hyperglycaemia management in hospital. Hypoglycaemia during hospitalization is associated with a nearly twofold increase in the risk of adverse events, which may be associated with increased disease severity and emphasizes the need to avoid hypoglycaemia during hospitalization. This study highlights the need for further studies on optimal glycaemic target in the non-critically ill patient population.

ACKNOWLEDGEMENTS

We would like to thank Sophie Dell’Aniello for her helpful advice regarding the statistical analysis of our study and Sylvie Mayer for her help in data extraction for our study.

CONFLICT OF INTEREST

All authors declare no conflict of interests relevant to this study.

AUTHOR CONTRIBUTIONS

Lan Deng wrote the manuscript. Wusiman Aibibula performed data analysis. Zahra Talat and Shaun Eintracht performed the data collection. All authors contributed to study design, interpretation of data, and reviewed and approved the final manuscript. Oriana Hoi Yun Yu is the guarantor of this work, had full access to the data and takes responsibility for the integrity of the data and data analyses.

DATA AVAILABILITY STATEMENT

The data used that supports the findings of this study are available from the corresponding author upon reasonable request and after approval is obtained to release data from the Research Ethics Committee at the Jewish General Hospital, Montréal, Canada.

ORCID

Kristian B. Filion https://orcid.org/0000-0001-6055-0088
Oriana Hoi Yun Yu https://orcid.org/0000-0003-4877-557X

REFERENCES

1. Umpierrez GE, Issacs SD, Bazzaran N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J. Clin. Endocrinol. Metab. 2002;87(3):978-982.
2. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet (London, England). 2009;373(9677):1798-1807.
3. Perez A, Jansen-Chaparros S, Saigi I, Bernal-Lopez MR, Minambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycaemia. J Diabetes. 2014;6(1):9-20.
4. Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPN J Parenter Enter. Nutr. 1998;22(2):77-81.
5. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32(10):2426-2432.
6. Montori VM, Bistrian BR, McMahon MM. Hyperglycemia in acutely ill patients. JAMA. 2002;288(17):2167-2169.
7. Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. Eur J Endocrinol. 2007;156(1):137-142.
8. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28(4):810-815.
9. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61(4):284-289.
10. McAlister FA, Man J, Bistritz L, Amad H, Tandon P. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care. 2003;26(5):1518-1524.
11. Ainla T, Baburin A, Teesalu R, Rahu M. The association between hyperglycaemia on admission and 180-day mortality in acute myocardial infarction patients with and without diabetes. Diabet Med. 2005;22(10):1321-1325.
12. Mowat A, Baum J. Chemotaxis of polymorphonuclear leucocytes from patients with diabetes mellitus. N Engl J Med. 1971;284(12):621-627.
13. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23(1):9-15.
14. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322(25):1769-1774.
15. Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res. 1998;90(4):181-190.
16. Marfella R, Nappo F, De Angelis L, Paolisso G, Tagliamonte MR, Giugliano D. Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care. 2000;23(5):658-663.
17. Kersten JR, Toller WG, Tessmer JP, Pagel PS, Warrtler DC. Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism. Am J Physiol Heart Circ Physiol. 2001;281(5):H2097-H2104.
18. Sheetz MJ, King GL. Molecular understanding of hyperglycaemia’s adverse effects for diabetic complications. JAMA. 2002;288(20):2579-2588.
19. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97(17):1695-1701.
20. McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am. 1995;9(1):1-9.
21. Gin H, Brottier E, Aubertin J. Influence of glycaemic normalisation by an artificial pancreas on phagocytic and bactericidal functions of granulocytes in insulin dependent diabetic patients. J Clin Pathol. 1984;37(9):1029-1031.
22. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabet Med. 1992;18(3):187-201.
23. Falcigna M, Freyberg RW, Almenoff PL, D’Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37(12):3001-3009.
24. American Diabetes A. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020. *Diabetes Care*. 2020;43(Suppl 1):S193-S202.

25. Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* 2012;97(1):49-58.

26. Wang YJ, Seggelke S, Hawkins RM, et al. Impact of glucose management team on outcomes of hospitalization in patients with type 2 diabetes admitted to the medical service. *Endocr Pract.* 2016;19:19.

27. Malcolm J, Halperin I, Miller DB, et al. In-Hospital Management of Diabetes. *Can J Diabetes*. 2018;1:S115-S123.

28. Harper W, Clement M, Goldenberg R, et al. Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes-2015 interim update. *Can J Diabetes*. 2015;39(4):250-252.

29. Quebec Becomes First Province to Publicly Reimburse INVOKANA™* for Type 2 Diabetes. CNW Web site. http://www.newswire.ca/news-releases/quebec-becomes-first-province-to-publicly-reimburse-invokana-for-type-2-diabetes-516947701.html. Published 2015. Accessed February 3, 2016.

30. Marfella R, Sasso FC, Siniscalchi M, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. *J. Clin. Endocrinol. Metab.* 2012;97(8):2862-2871.

31. Marfella R, Sasso FC, Cacciapuoti F, et al. Tight glycemic control may increase regenerative potential of myocardium during acute infarction. *J. Clin. Endocrinol. Metab.* 2012;97(3):933-942.

32. Sasso FC, Rinaldi L, Lascar N, et al. Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes. *J Diabetes Res*. 2018;2018:3106056.

33. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *J Am Coll Cardiol.* 1995;26(1):57-65.

34. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med*. 2009;360(13):1283-1297.

35. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. *Eur Heart J.* 2005;26(7):650-661.

36. Cheung NW, Wong VW, McLean M. The Hyperglycemia: intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. *Diabetes Care*. 2006;29(4):765-770.

37. Yamada T, Shojima N, Hara K, Noma H, Yamauchi T, Kadowaki T. Glycemic control, mortality, secondary infection, and hypoglycemia in critically ill pediatric patients: a systematic review and network meta-analysis of randomized controlled trials. *Intensive Care Med.* 2017;43(9):1427-1429.

38. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ*. 2009;180(8):821-827.

39. Umpierrez GE, Palacio A, Smiley D. Sliding scale insulin use: myth or insanity? *Am J Med*. 2007;120(7):563-567.

40. Majumdar SR, Hemmelgarn BR, Lin M, McBrien K, Manns BJ, Tonelli M. Hypoglycemia associated with hospitalization and adverse events in older people: population-based cohort study. *Diabetes Care*. 2013;36(11):3585-3590.

41. Yeh JS, Sung SH, Huang HM, et al. Hypoglycemia and risk of vascular events and mortality: a systematic review and meta-analysis. *Acta Diabetol*. 2016;53(3):377-392.

42. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med*. 2010;363(15):1410-1418.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

*How to cite this article:* Deng L, Alibibula W, Talat Z, et al. The association between glycaemic control during hospitalization and risk of adverse events: A retrospective cohort study. *Endocrinol Diab Metab*. 2021;4:e00268. [https://doi.org/10.1002/edm2.268](https://doi.org/10.1002/edm2.268)